UBS Group’s CERo Therapeutics CERO Stock Holding History

UBS Group’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6	Closed	-$30	–	11285
2025 Q3	$30	Sell	6 -2,619	-100%	-$19.3K	﹤0.01%	10079
2025 Q2	$25.3K	Buy	2,625 +491	+23%	+$6.11K	﹤0.01%	8289
2025 Q1	$31.2K	Buy	+2,134	New	+$84.3K	﹤0.01%	7920
2023 Q1	–	Sell	-1	Closed	-$29.7K	–	10516
2022 Q4	$29.7K	Hold	1	–	–	﹤0.01%	7250
2022 Q3	$15K	Buy	+1	New	+$20.1K	﹤0.01%	7834
2022 Q2	–	Hold	0	–	–	–	8737

UBS Group's CERO Position: Q4 2025 in Review

UBS Group sold out of CERo Therapeutics (CERO) in Q4 2025, closing a stake of 6 shares — an estimated $30 sold.

UBS Group first reported a position in CERO in Q3 2022 and held it in 5 quarters. The position peaked at $31.2K in Q1 2025. 0 funds tracked by Wall St. Rank hold CERO as of Q4 2025.

UBS Group reported no remaining CERo Therapeutics position as of Q4 2025 after selling out during the quarter.
UBS Group sold 6 CERo Therapeutics shares in Q4 2025, an estimated $30.
UBS Group first reported a position in CERo Therapeutics in Q3 2022 and held it in 5 quarters.
UBS Group's CERo Therapeutics position peaked at $31.2K in Q1 2025.
0 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.